1991 - Pharmalink founded by Mikael Bender and Bengt Julander
1992-2003 - Founders build a pharmaceutical company based on sales and marketing. Pharmalink introduces 15 products to the market, with a focus on the Northern Europe
2003 - Product portfolio sold to MEDA AB returning funds to investors. Pharmalink retains its non-marketed projects as a platform to deliver on new strategy as development-only
2004 - Pharmalink enters a collaboration with West Pharmaceutical Services (later acquired by Archimedes Pharma) to develop Nefecon® for IgA nephropathy
2006 - Pharmalink acquires BusulipoTM from Karolinska Institute scientists
2007 - Pharmalink recruits new Managing Director, to drive evolved business model and focus on projects in clinical phase
2008 - Pharmalink reports positive Phase III results for Xepol®
2009 - Pharmalink reports promising results in Phase IIa trial with Nefecon®
2010 - Neurology project Xepol® (in Phase III) acquired by Grifols SA. Preclinical project Applet (acute rejection/organ transplants) is divested for strategic reasons
2011 - Pharmalink gains exclusive rights to Nefecon’s® formulation technology Targit® from Archimedes Pharma. Industrifonden leads new funding round
2013 – Industrifonden and Investinor co-lead SEK96m investment to enable preparation and completion of pivotal studies of Busulipo and Nefecon, to seek commercial partners for its products outside the Nordic region, and to facilitate in-licensing or acquisition of additional opportunities for commercialization in the Nordic region.